

Product data sheet



MedKoo Cat#: 555217 Name: HMN-154 CAS: 173528-92-2 Chemical Formula: C ₂₀ H ₁₈ N ₂ O ₃ S Exact Mass: 366.1038 Molecular Weight: 366.435	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:

HMN-154 is a benzenesulfonamide anticancer agent. HMN-154 inhibits DNA binding of NF- κ B to the human major histocompatibility complex class II human leukocyte antigen DRA Y-box sequence in a dose-dependent manner.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	15.0	40.93

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.73 mL	13.65 mL	27.29 mL
5 mM	0.55 mL	2.73 mL	5.46 mL
10 mM	0.27 mL	1.36 mL	2.73 mL
50 mM	0.06 mL	0.27 mL	0.55 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

1. Tanaka H, Ohshima N, Hidaka H. Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. *Mol Pharmacol.* 1999 Feb;55(2):356-63. doi: 10.1124/mol.55.2.356. PMID: 9927629.

In vivo study

TBD

7. Bioactivity

Biological target:

HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC₅₀ values of 0.0026 and 0.003 μ g/mL, respectively.

In vitro activity

Furthermore, HMN-154 inhibits DNA binding of NF- κ B to the human major histocompatibility complex class II human leukocyte antigen DRA Y-box sequence in a dose-dependent manner.

Reference: *Mol Pharmacol.* 1999 Feb;55(2):356-63. <https://pubmed.ncbi.nlm.nih.gov/9927629/>

Product data sheet



In vivo activity

TBD

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.